Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment

Journal of Clinical Pharmacology

Volumn 58, Issue 3, 2018, Pages 357-363

  Marzin, Kristell ^a   Kretschmar, Gunther ^a   Luedtke, Doreen ^a   Kraemer, Sandrine ^b   Kuelzer, Raimund ^a   Schlenker Herceg, Rozsa ^c   Schmid, Ulrike ^a   Schnell, David ^a   Dallinger, Claudia ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM   (France)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

absorption; adverse drug event; biological availability; liver function tests; protein tyrosine kinases

Indexed keywords

GELATIN; NINTEDANIB; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MALE; MAXIMUM CONCENTRATION; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; NAUSEA; OPEN STUDY; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; PRURITUS; SINGLE DRUG DOSE; SKIN IRRITATION; BLOOD; CLINICAL TRIAL; LIVER DISEASE; METABOLISM; MIDDLE AGED;

AGED; FEMALE; HUMANS; INDOLES; LIVER DISEASES; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS;

EID: 85041638653     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.1025     Document Type: Article

References (21)

1. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68:4774–4782.
2. Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–1445.
3. BI. Vargatef (nintedanib) Summary of Product Characteristics. 2017. http://www.ema.europa.eu/ema/. Accessed June 21, 2017.
4. BI. Ofev (nintedanib) Summary of Product Characteristics. 2017. http://www.ema.europa.eu/ema/. Accessed June 21, 2017.
5. ® (nintedanib) Prescribing Information. 2017. https://www.ofev.com/. Accessed June 21, 2017.
6. Dallinger C, Trommeshauser D, Marzin K, Liesener A, Kaiser R, Stopfer P. Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. J Clin Pharmacol. 2016;56:1387–1394.
7. Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011;41:297–311.
8. Mross K, Stefanic M, Gmehling, D, et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2010;16:311–319.
9. Okamoto I, Kaneda H, Satoh T, et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther. 2010;9:2825–2833.
10. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol. 2011;22:1374–1381.
11. Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1382–1392.
12. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res. 2010;16:2881–2889.
13. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143–155.
14. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079–1087.
15. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–2082.
16. Hanna NH, Kaiser R, Sullivan RN, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial. Lung Cancer. 2016;102:65–73.
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–649.
18. European Medicines Agency. 2005. Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003122.pdf. Accessed March 7, 2017.
19. Food and Drug Administration. 2014. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205832Orig1s000ClinPharmR.pdf. Accessed March 7, 2017.
20. Food and Drug Administratiation. Guidance for Industry. Pharmacokinetics in patients with impaired hepatic function – study design, data analysis, and Impact on dosing and labeling. 2003. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072123.pdf. Accessed March 7, 2017.
21. Eisen T, Shparyk Y, Macleod N, et al. Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study. Invest New Drugs. 2013;31:1283–1293.